Risk of arrhythmia in type I myotonic dystrophy: The role of clinical and genetic variables

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 7, 2009, Pages 790-793

  Cudia, P ^a   Bernasconi, P ^a   Chiodelli, R ^b   Mangiola, F ^c   Bellocci, F ^d   Dello Russo, A ^d   Angelini, C ^e   Romeo, V ^e   Melacini, P ^e   Politano, L ^f   Palladino, A ^f   Nigro, G ^f   Siciliano, G ^g   Falorni, M ^g   Bongiorni, M G ^h   Falcone, C ^a   Mantegazza, R ^a   Morandi, L ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UILDM   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h CISANELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYOTONIC DYSTROPHY; PATIENT INFORMATION; PATIENT SELECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ARRHYTHMIAS, CARDIAC; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOTONIC DYSTROPHY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; YOUNG ADULT;

EID: 67650470235     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.162594     Document Type: Article

References (23)

1. Brook JD, McCurrache ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
2. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007;20:572-6.
3. Sovari AA, Bodine CK, Farokhi F. Cardiovascular manifestations of myotonic dystrophy-1. Cardiol Rev 2007;15:191-4.
4. Pelargonio G, Dello Russo A, Sanna T, et al. Myotonic dystrophy and the heart. Heart 2002;88:665-70.
5. Phillips MF, Harper PS. Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997;33:13-22.
6. Mathieu J, Allard P, Potvin L, et al. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999;52:1658-62.
7. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-97.
8. Finsterer J, Gharehbaghi-Schnell E, Stollberger C. Relation of cardiac abnormalities and CTG-repeat size in myotonic dystrophy. Clin Genet 2001;59:350-5.
9. Groh WJ, Lowe MR, Zipes DP. Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length. J Cardiovasc Electrophysiol 2002;13:444-8.
10. Melacini P, Villanova C, Menegazzo E, et al. Correlation between cardiac involvement and CTG trinucleotide repeat lenght in myotonic dystrophy. J Am Coll Cardiol 1995;25:239-45.
11. Antonini G, Giubilei F, Mammarella A, et al. Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology 2000;55:1207-9.
12. Lazarus A, Varin J, Ounnoughene Z, et al. Relationship among electrophysiological findings and clinical status, heart function and extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:1041-6.
13. Hayashi Y, Ikeda U, Kojo T, et al. Cardiac abnormalities and cytosine-thymine-guanine trinucleotide repeats in myotonic dystrophy. Am Heart J 1997;134:292-7.
14. Sabovic M, Medica I, Logar N, et al. Relation of CTG expansion and clinical variables to electrocardiogram conduction abnormalities and sudden death in patients with myotonic dystrophy. Neuromusc Dis 2003;13:822.
15. Brugnoni R, Morandi L, Brambati B, et al. A new non radioactive method for the screening and prenatal diagnosis of myotonic dystrophy patients. J Neurol 1998;245:289-93.
16. The International Myotonic Dystrophy Consortium (IDMC). New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology 2000;54:1218-21.
17. Epstein AE, DiMarco JP, Ellenboghen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart association Task Force on practice guidelines (ACC/AHA/NASPE Committee to update the 2002 Pacemaker Guidelines). Circulation 2008;117:350-408.
18. Mathieu J, Boivin H, Meunier D, et al. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001;56:336-40.
19. Groh WJ, Lowe MR, Simmons ZS, et al. Familial clustering of muscular and cardiac involvement in myotonic dystrophy type 1. Muscle Nerve 2005;31:719-24.
20. Anvret M, Ahlberg G, Grandell U, et al. Larger expansion of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. Hum Mol Genet 1993;2:1397-400.
21. Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Gen 2006;15:2087-97.
22. 2+- ATPase in myotonic dystrophy type 1. Hum Mol Gen 2005;14:2189-200.
23. Yadava RS, Frenzel- Mc Cardell CD, Yu Q, et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet 2008;40:61-8.